Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16726882 | 1.00 | GAA (0.63) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL11346251 | 0.92 | GAA (0.53) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL6890669 | 0.86 | GAA (0.50) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL24255365 | 0.85 | TSHR (0.49) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL27443069 | 0.85 | TSHR (0.49) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2575940 | 0.85 | TSHR (0.49) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL28513329 | 0.85 | TSHR (0.49) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL14728290 | 0.85 | TSHR (0.49) | GAAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL26353713 | 0.85 | GAA (0.69) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL16726879 | 0.84 | RECQL (0.48) | GAAALDH1A1CYP1A2CYP2C9RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| WO-2013068874-A1 | ANTIBODY-DRUG CONJUGATES | PFIZER INC. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | GAA 438/4885ALDH1A1 868/4885CYP1A2 2119/4885 |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | CD74, CD63, CD47 | GAA 438/4885ALDH1A1 868/4885CYP1A2 2119/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | GAA 529/4885ALDH1A1 1177/4885CYP1A2 2172/4885 |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | KLK3, PTMS, DDOST | GAA 557/4885ALDH1A1 2041/4885CYP1A2 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.